PDF(Pubmed)
Abstract：
OBJECTIVE: To evaluate lacrimal gland adenoid cystic carcinoma (LGACC) of prognosis in patients who underwent different treatment regimens.
METHODS: We searched PubMed, EMBASE, and the Cochrane Library for studies done on the treatment of LGACC, between January 1987 and April 2022. A Meta-analysis was conducted to pool the 5-year overall survival rate (OR), and the 5-year recurrence rate (RR) and 5-year metastasis rate (MR) were assessed.
RESULTS: The 30 studies involved 585 patients were included in the Meta-analysis. The pooled 5-year OR with surgery alone was 50%, the 5-year RR was 63%, and the 5-year MR was 34%. The pooled 5-year OR with surgery and adjuvant radiotherapy combined was 67% (95%CI 61%,73%), the 5-year RR was 41%, and the 5-year MR was 35%. The pooled 5-year OR with surgery and adjuvant chemoradiotherapy combined was 72% (95%CI 59%, 84%), the 5-year RR was 48%, and the 5-year MR was 36%. The pooled 5-year OR with surgery, intra-arterial cytoreductive chemotherapy, and adjuvant chemoradiotherapy combined was 78% (95%CI 68%, 89%), the 5-year RR was 15%, and the 5-year MR was 27%.
CONCLUSIONS: Comprehensive treatment is more effective than surgery alone. Surgery combined with intra-arterial chemotherapy and adjuvant chemoradiotherapy seems to add value to the therapeutic effect of comprehensive treatment of LGACC but further high-quality research is required to validate this.
METHODS: We searched PubMed, EMBASE, and the Cochrane Library for studies done on the treatment of LGACC, between January 1987 and April 2022. A Meta-analysis was conducted to pool the 5-year overall survival rate (OR), and the 5-year recurrence rate (RR) and 5-year metastasis rate (MR) were assessed.
RESULTS: The 30 studies involved 585 patients were included in the Meta-analysis. The pooled 5-year OR with surgery alone was 50%, the 5-year RR was 63%, and the 5-year MR was 34%. The pooled 5-year OR with surgery and adjuvant radiotherapy combined was 67% (95%CI 61%,73%), the 5-year RR was 41%, and the 5-year MR was 35%. The pooled 5-year OR with surgery and adjuvant chemoradiotherapy combined was 72% (95%CI 59%, 84%), the 5-year RR was 48%, and the 5-year MR was 36%. The pooled 5-year OR with surgery, intra-arterial cytoreductive chemotherapy, and adjuvant chemoradiotherapy combined was 78% (95%CI 68%, 89%), the 5-year RR was 15%, and the 5-year MR was 27%.
CONCLUSIONS: Comprehensive treatment is more effective than surgery alone. Surgery combined with intra-arterial chemotherapy and adjuvant chemoradiotherapy seems to add value to the therapeutic effect of comprehensive treatment of LGACC but further high-quality research is required to validate this.
摘要：
目的：评价泪腺腺样囊性癌(LGACC)患者接受不同治疗方案的预后。
方法：我们搜索了PubMed，EMBASE,以及Cochrane图书馆对LGACC治疗的研究，1987年1月至2022年4月。进行了Meta分析，以汇集5年总生存率（OR），并评估5年复发率（RR）和5年转移率（MR）。
结果：30项研究纳入585例患者纳入Meta分析。仅手术合并的5年OR为50％，5年期RR为63%，5年MR为34%。合并手术和辅助放疗的5年OR为67％（95CI61％，73%），5年期RR为41%，5年MR为35%。合并手术和辅助放化疗的5年OR为72％（95CI59％，84%），5年期RR为48%，5年MR为36%。合并的5年或手术，动脉内细胞减灭术化疗，和辅助放化疗联合占78%(95CI68%，89%），5年期RR为15%，5年MR为27%。
结论：综合治疗比单独手术更有效。手术联合动脉内化疗和辅助放化疗似乎为LGACC综合治疗的治疗效果增加了价值，但需要进一步的高质量研究来验证这一点。
方法：我们搜索了PubMed，EMBASE,以及Cochrane图书馆对LGACC治疗的研究，1987年1月至2022年4月。进行了Meta分析，以汇集5年总生存率（OR），并评估5年复发率（RR）和5年转移率（MR）。
结果：30项研究纳入585例患者纳入Meta分析。仅手术合并的5年OR为50％，5年期RR为63%，5年MR为34%。合并手术和辅助放疗的5年OR为67％（95CI61％，73%），5年期RR为41%，5年MR为35%。合并手术和辅助放化疗的5年OR为72％（95CI59％，84%），5年期RR为48%，5年MR为36%。合并的5年或手术，动脉内细胞减灭术化疗，和辅助放化疗联合占78%(95CI68%，89%），5年期RR为15%，5年MR为27%。
结论：综合治疗比单独手术更有效。手术联合动脉内化疗和辅助放化疗似乎为LGACC综合治疗的治疗效果增加了价值，但需要进一步的高质量研究来验证这一点。
